Renowned Transplant Clinician to Lead CareDx Global Medical Affairs

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025.

Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation and Cardiovascular Medicine, and has served as Section Chief of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support at Stanford University since 2017.

Internationally recognized for his leadership and innovation in transplantation, Dr. Teuteberg has held prominent roles in the American Society of Transplantation (AST) and the International Society for Heart and Lung Transplantation (ISHLT), including serving as President of ISHLT and chairing multiple key committees and task forces. He has also served as principal investigator for the Surveillance HeartCare Outcomes Registry (SHORE) study, advancing the science of noninvasive rejection surveillance and outcomes in heart transplantation. Dr. Teuteberg’s contributions to multicenter clinical trials and guideline committees have helped shape the practice of heart transplantation worldwide.

“I am honored to join CareDx at such a pivotal time for the field of transplantation,” said Dr. Teuteberg. “Through my research, particularly as principal investigator of the SHORE study, I have witnessed the transformative impact of data-driven innovation on the patient experience and their outcomes. I look forward to helping CareDx drive the next generation of innovative solutions for transplant patients and the clinicians who care for them.”

“Dr. Teuteberg’s deep clinical expertise and leadership in transplant medicine are a tremendous fit for CareDx,” said John Hanna, President and Chief Executive Officer of CareDx. “His commitment to advancing patient care and his track record of clinical innovation will be invaluable as we continue to deliver on our mission to create life-changing solutions that enable transplant patients to thrive.”

Dr. Teuteberg will lead CareDx’s Medical Affairs activities globally, including its Medical Directors, Medical Science Liaisons, and clinical research operations, to further advance the company’s leadership and impact in the field of transplantation.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit www.caredx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx’s filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed by CareDx with the SEC on August 6, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251027720132/en/